184 related articles for article (PubMed ID: 26175414)
1. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Wu SC; Li LS; Kopp N; Montero J; Chapuy B; Yoda A; Christie AL; Liu H; Christodoulou A; van Bodegom D; van der Zwet J; Layer JV; Tivey T; Lane AA; Ryan JA; Ng SY; DeAngelo DJ; Stone RM; Steensma D; Wadleigh M; Harris M; Mandon E; Ebel N; Andraos R; Romanet V; Dölemeyer A; Sterker D; Zender M; Rodig SJ; Murakami M; Hofmann F; Kuo F; Eck MJ; Silverman LB; Sallan SE; Letai A; Baffert F; Vangrevelinghe E; Radimerski T; Gaul C; Weinstock DM
Cancer Cell; 2015 Jul; 28(1):29-41. PubMed ID: 26175414
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Inactive Conformation of JAK2 in Hematological Malignancies.
Silvennoinen O; Hubbard SR
Cancer Cell; 2015 Jul; 28(1):1-2. PubMed ID: 26175407
[TBL] [Abstract][Full Text] [Related]
3. How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
Kong X; Sun H; Pan P; Li D; Zhu F; Chang S; Xu L; Li Y; Hou T
Sci Rep; 2017 Aug; 7(1):9088. PubMed ID: 28831147
[TBL] [Abstract][Full Text] [Related]
4. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Meyer SC; Keller MD; Chiu S; Koppikar P; Guryanova OA; Rapaport F; Xu K; Manova K; Pankov D; O'Reilly RJ; Kleppe M; McKenney AS; Shih AH; Shank K; Ahn J; Papalexi E; Spitzer B; Socci N; Viale A; Mandon E; Ebel N; Andraos R; Rubert J; Dammassa E; Romanet V; Dölemeyer A; Zender M; Heinlein M; Rampal R; Weinberg RS; Hoffman R; Sellers WR; Hofmann F; Murakami M; Baffert F; Gaul C; Radimerski T; Levine RL
Cancer Cell; 2015 Jul; 28(1):15-28. PubMed ID: 26175413
[TBL] [Abstract][Full Text] [Related]
5. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
[TBL] [Abstract][Full Text] [Related]
6. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
[TBL] [Abstract][Full Text] [Related]
7. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable.
Codilupi T; Szybinski J; Arunasalam S; Jungius S; Dunbar AC; Stivala S; Brkic S; Albrecht C; Vokalova L; Yang JL; Buczak K; Ghosh N; Passweg JR; Rovo A; Angelillo-Scherrer A; Pankov D; Dirnhofer S; Levine RL; Koche R; Meyer SC
Clin Cancer Res; 2024 Feb; 30(3):586-599. PubMed ID: 37992313
[TBL] [Abstract][Full Text] [Related]
8. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.
Arwood ML; Liu Y; Harkins SK; Weinstock DM; Yang L; Stevenson KE; Plana OD; Dong J; Cirka H; Jones KL; Virtanen AT; Gupta DG; Ceas A; Lawney B; Yoda A; Leahy C; Hao M; He Z; Choi HG; Wang Y; Silvennoinen O; Hubbard SR; Zhang T; Gray NS; Li LS
Cell Chem Biol; 2023 Jun; 30(6):618-631.e12. PubMed ID: 37290440
[TBL] [Abstract][Full Text] [Related]
9. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
10. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
[TBL] [Abstract][Full Text] [Related]
11. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.
Sadras T; Heatley SL; Kok CH; McClure BJ; Yeung D; Hughes TP; Sutton R; Ziegler DS; White DL
Cancer Genet; 2017 Oct; 216-217():86-90. PubMed ID: 29025600
[TBL] [Abstract][Full Text] [Related]
12. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
[TBL] [Abstract][Full Text] [Related]
13. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
14. Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
Brasca MG; Gnocchi P; Nesi M; Amboldi N; Avanzi N; Bertrand J; Bindi S; Canevari G; Casero D; Ciomei M; Colombo N; Cribioli S; Fachin G; Felder ER; Galvani A; Isacchi A; Motto I; Panzeri A; Donati D
Bioorg Med Chem; 2015 May; 23(10):2387-407. PubMed ID: 25882525
[TBL] [Abstract][Full Text] [Related]
15. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
[TBL] [Abstract][Full Text] [Related]
16. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Pikman Y; Alexe G; Roti G; Conway AS; Furman A; Lee ES; Place AE; Kim S; Saran C; Modiste R; Weinstock DM; Harris M; Kung AL; Silverman LB; Stegmaier K
Clin Cancer Res; 2017 Feb; 23(4):1012-1024. PubMed ID: 28151717
[No Abstract] [Full Text] [Related]
18. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
19. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
[TBL] [Abstract][Full Text] [Related]
20. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
